SEC Form 4 · accession 0001437749-26-021519
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel George Wildman
Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 10:03 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001668243
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right ot buy)F1 | $34.99 | Jun 22, 2026 | A | 10,000 | A | — | Jun 22, 2036 | Ordinary Shares | 10,000 | 10,000 | D |
| Restricted Stock UnitF2,F3 | — | Jun 22, 2026 | A | 8,000 | A | — | — | Ordinary Shares | 8,000 | 8,000 | D |
Explanation of responses
- F1The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- F3The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.